Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) insider Jeffrey Arcara bought 1,003 shares of the firm’s stock in a transaction on Friday, November 13th. The shares were acquired at an average price of $10.54 per share, for a total transaction of $10,571.62. Following the transaction, the insider owned 4,500 shares in the company, valued at approximately $47,430. This represents a 28.68% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Jeffrey Arcara also recently made the following trade(s):
- On Thursday, November 12th, Jeffrey Arcara purchased 497 shares of Corvus Pharmaceuticals stock. The stock was bought at an average price of $11.12 per share, with a total value of $5,526.64.
- On Wednesday, November 11th, Jeffrey Arcara purchased 3,000 shares of Corvus Pharmaceuticals stock. The stock was bought at an average price of $11.46 per share, with a total value of $34,380.00.
Corvus Pharmaceuticals Price Performance
Shares of NASDAQ:CRVS opened at $10.64 on Monday. The company has a market capitalization of $897.48 million, a P/E ratio of -14.99 and a beta of 1.57. Corvus Pharmaceuticals, Inc. has a 1 year low of $6.39 and a 1 year high of $26.95. The business’s 50 day simple moving average is $11.18 and its 200 day simple moving average is $14.04.
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). On average, sell-side analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.81 EPS for the current fiscal year.
Key Corvus Pharmaceuticals News
Here’s some of the latest news about CRVS:
- Positive Sentiment: A Globe and Mail headline includes Corvus among healthcare stocks analysts are bullish on, though the article details provided do not specify a rating or price target. Analysts Are Bullish on Top Healthcare Stocks: Corvus Pharmaceuticals (CRVS), Achieve Life Sciences (QUIT)
- Negative Sentiment: HC Wainwright cut estimates across multiple periods. It now expects a $1.04-per-share loss in 2027, versus its prior $0.80 loss estimate, and a $0.90 loss in 2028, versus $0.37 previously. It also reduced its 2029 forecast from near breakeven to a $0.43 loss and lowered its 2030 profit estimate to $0.45 from $0.67. The revisions suggest a slower improvement in earnings and could weigh on investor sentiment. HC Wainwright earnings estimate updates
Institutional Trading of Corvus Pharmaceuticals
Several large investors have recently made changes to their positions in CRVS. BlackRock Inc. bought a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at $106,654,000. Vivo Capital LLC raised its holdings in shares of Corvus Pharmaceuticals by 25.6% during the 1st quarter. Vivo Capital LLC now owns 2,805,816 shares of the company’s stock worth $41,049,000 after buying an additional 571,250 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Corvus Pharmaceuticals by 17.8% during the 2nd quarter. Wellington Management Group LLP now owns 2,731,632 shares of the company’s stock worth $40,811,000 after buying an additional 413,115 shares during the last quarter. Perceptive Advisors LLC lifted its position in shares of Corvus Pharmaceuticals by 231.1% during the 1st quarter. Perceptive Advisors LLC now owns 2,292,441 shares of the company’s stock worth $33,538,000 after buying an additional 1,600,000 shares during the last quarter. Finally, Commodore Capital LP bought a new stake in shares of Corvus Pharmaceuticals during the 1st quarter worth $33,045,000. Institutional investors and hedge funds own 46.64% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on CRVS. Ladenburg Thalmann & Co. Inc. raised Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. Mizuho set a $27.00 price target on Corvus Pharmaceuticals in a research note on Thursday, October 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, September 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research report on Monday, October 26th. Finally, Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.83.
Read Our Latest Analysis on CRVS
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.
Featured Articles
- Five stocks we like better than Corvus Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
